Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Guida M, Riccobon A, BIASCO, GUIDO, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R, Italian Melanoma Intergroup
Publikováno v:
Melanoma Research. 16:317-323
Cytokines play a crucial role in the host's immune response. In melanoma patients, cytokine profiles seems to be related to the clinical course and their imbalance could be associated to tumour progression. Thus, we studied a panel of baseline cytoki
Autor:
Katherine S. Panageas, W. Hwu, Carolyn J. Quinn, P. O. Livingston, Paul B. Chapman, Jedd D. Wolchok, Lawrence J. Williams
Publikováno v:
Melanoma Research. 12:381-387
Phase II studies of biochemotherapy in metastatic melanoma patients have reported response rates of 47-63%. Even though these were highly selected patients, we were intrigued by these promising response rates and began using this regimen as standard
Autor:
J. Rice, Omar Eton, Nicholas E. Papadopoulos, Carl Plager, Agop Y. Bedikian, Maria I. Colome, J. Jack Lee, Merrick I. Ross, Sigrid Ring, Jeffrey E. Lee, Paul F. Mansfield, Sewa S. Legha, Antonio C. Buzaid, Robert S. Benjamin, Eric A. Strom
Publikováno v:
Melanoma Research. 8:549-556
Our results with concurrent biochemotherapy in patients with stage IV melanoma have been encouraging. Based on these data, we conducted a phase II study to determine the clinical and histological response rate to neoadjuvant concurrent biochemotherap
Autor:
Tamar Safra, Ilan G. Ron, Einat Even Sapir, David Sarid, Moshe Inbar, Noam Asna, Shlomo Schneebaum, Ur Metser, Larisa Ryvo
Publikováno v:
Melanoma research. 16(1)
Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases. Twenty-three patients with advanced ino
Autor:
Marcelo Sánchez, Susana Puig, Joseph Malvehy, Marta Martin, Pere Gascón, Begoña Mellado, Rosa M. Martí, Teresa Castel, Joseph Herrero, María González Cao, Cristina Carrera, Carlos Conill
Publikováno v:
Melanoma research. 16(1)
The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma. Treatment consisted of temozolomide (150 mg/m per
Autor:
Kevin B. Kim, Mandy S Harting
Publikováno v:
Melanoma research. 14(6)
Patients with advanced vulvovaginal mucosal melanoma generally have a dismal prognosis, and no effective systemic therapy for the disease has been reported. The objective of this retrospective clinical study was to assess the clinical benefit of bioc
Publikováno v:
Melanoma research. 14(6)
We have observed that an early increase in the CD4+/CD8+ ratio of metastatic melanoma patients during chemoimmunotherapy is the most favourable independent prognostic factor. In this study, 87 patients with metastatic melanoma were monitored for peri
Publikováno v:
Melanoma research. 13(2)
The prognosis of patients with metastatic melanoma remains poor and there is a need to develop new regimens with low toxicity. We investigated a novel outpatient regimen combining oral and intravenous chemotherapy with daily subcutaneous bleomycin. T
Autor:
S. S. Legha, Cesar H. Carrasco, Mary Ann V. Gianan, Cynthia Hodges, Nicholas E. Papadopoulos, Agop Y. Bedikian, Robert S. Benjamin, Omar Eton, Antonio C. Buzaid, Mary Jo East
Publikováno v:
Melanoma research. 9(5)
For melanoma, in-transit metastases (ITMs) are a harbinger of systemic disease in over 70% of patients and thus warrant a systemic approach to management. In this study, previously untreated patients with ITMs (n=15) received a systemic regimen of 'C
Autor:
Agop Y. Bedikian, C. Plager, J. Sussman, J. Jack Lee, Francis Ali-Osman, P. G. Braunschweiger, Nicholas E. Papadopoulos, A. C. Buzaid, Elizabeth A. Grimm, S. S. Legha, Clay M. Anderson, Omar Eton
Publikováno v:
Melanoma research. 8(2)
The combination of cisplatin-based chemotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha), referred to as biochemotherapy, has produced overall response rates of greater than 50% in advanced melanoma patients, with durable complete r